The National Institute for Health and Care Excellence (NICE) has approved glecaprevir–pibrentasvir (Maviret) as a treatment option for chronic hepatitis C.
Glecaprevir–pibrentasvir is recommended for the treatment of adults with chronic hepatitis C. The eligible patient pool includes those infected with HCV genotypes 1-6, with or without compensated cirrhosis, with untreated disease or those having received previous treatment with interferon-based therapies or sofosbuvir + ribavirin.
Individuals previously treated with a NS3/4A and/or NS5A inhibitor are not eligible for treatment with glecaprevir–pibrentasvir. Recommended dosage for glecaprevir–pibrentasvir is 300 mg/120 mg once daily taken orally for a period of 8, 12 or 16 weeks based on the genotype, cirrhosis status and prior treatment history of the patient.
Clinical evidence suggests glecaprevir–pibrentasvir to work as effectively as most direct-acting antiviral drugs currently recommended by NICE. The NICE also considers the cost-effectiveness of glecaprevir–pibrentasvir to be substantially below the acceptable limits.
The therapy is to be used only when it is provided by the company at a price comparable with or lower than that agreed with the Commercial Medicines Unit.
